en · de · es · fr · pt
sr9009-notes.peptides4088.com › Wiki › Sr9009 Identity And Mechanism — Deep Dive

Sr9009 Identity And Mechanism — Deep Dive

By Editorial Desk · published 2025-07-27 · last reviewed 2025-09-11 · Wiki

This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-09-11. Anything still debated is marked as such rather than presented as settled.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Related pages on this site

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Background from the literature

== Trial and conviction == Thaçi made his initial court appearance on 9 November 2020; he pleaded not guilty. His three co-defendants also pleaded not guilty. The trial opened in April 2023. In December 2024, the KSC filed a new case against Thaçi, in which he was charged with three counts of obstruction of official persons in performing official duties, four counts of violating secrecy of proceedings and four counts of contempt of court over "alleged unlawful efforts to influence witness testimonies" during the trial. In March 2025, Thaçi was temporarily released to visit his ailing father in Pristina. After his father died shortly later, Thaçi was again temporarily released to allow him to visit his father's grave, having been previously barred from attending the funeral. On 16 September 2026, Thaçi was convicted and sentenced to 25 years' imprisonment. Based on evidence from 273 witnesses, 5,467 pieces of evidence, the KSC found Thaçi guilty together with Veseli, Selemi, and Krasniqi of the murder of 96 political opponents and alleged collaborators with Serbian forces in the 1990s, the illegal detention of 385 people, the torture of 303 and the cruel treatment of 49 as part of a joint criminal enterprise. He and his co-accused were cleared of six charges of crimes against humanity.

==== Nucleic acid-based molecules ==== Nanogels are advantageous carriers of small, nucleic-acid based molecules that can be employed to treat a variety of diseases. Examples of three different types of molecules that fall into this category, oligonucleotides, miRNA, and nucleoside analogs, are discussed here. In one study, cationic synthetic nanogels modified with insulin and transferrin were synthesized to transport oligonucleotides, a possible therapeutic and diagnostic tool for neurodegenerative disorders, to the brain. These nanogels successfully localized through an in vitro model of the blood-brain barrier and accumulated in the brain in a mouse model. With the treatment of cardiovascular diseases in mind, polysaccharide-based nanogels have been functionalized with fucoidan to target overexpressed P-selectin receptors on platelets and endothelial cells. After loading with miRNA, these nanogels bound to platelets and became internalized by an endothelial cell line. Nanogels have also been used to encapsulate phosphorylated nucleoside analogs, or active forms of anticancer therapeutics. In one study, nanogels loaded with nucleoside 5'-triphosphates underwent surface modifications and successfully bound to overexpressed folate receptors on breast cancer cells. These nanogels were then internalized by the cells and produced a significant increase in cytotoxicity compared to control groups.

== See also == Americanization Anti-American sentiment American stereotypes Cocacolonization Cultural imperialism Debates over Americanization Military globalization McDonaldization Pax Americana Sovietization Sovietization of the Baltic states Soviet socialist patriotism United States in the 1950s

The normal form of ice on the surface of Earth is ice Ih, a phase that forms crystals with hexagonal symmetry. Another with cubic crystalline symmetry, ice Ic, can occur in the upper atmosphere. As the pressure increases, ice forms other crystal structures. As of 2024, twenty have been experimentally confirmed and several more are predicted theoretically. The eighteenth form of ice, ice XVIII, a face-centred-cubic, superionic ice phase, was discovered when a droplet of water was subject to a shock wave that raised the water's pressure to millions of atmospheres and its temperature to thousands of degrees, resulting in a structure of rigid oxygen atoms in which hydrogen atoms flowed freely. When sandwiched between layers of graphene, ice forms a square lattice. The details of the chemical nature of liquid water are not well understood; some theories suggest that its unusual behavior is due to the existence of two liquid states.

Sources: en.wikipedia.org

Reference notes

transcytosis The transport of molecules across the interior of a cell, i.e. through the cytoplasm, especially a polarized cell such as an epithelial cell with contrasting apical and basal surfaces, thereby providing a spatially oriented transport system. Molecules undergoing transcytosis are usually contained within vesicles.

The signal change manifests itself in an increase or decrease in the current (electrical) or in a change in the intensity or wavelength of the fluorescence emission (optical). Depending on the type of application, both electrical or optical signal transmission can be advantageous. For sensitive measurement of electronic changes, field-effect transistors (FET) are often used in which the flow of charges within the SWCNTs is measured. The FET structures allow easy on-chip integration and can be parallelized to detect multiple target analytes simultaneously. However, such sensors are more invasive for in vivo applications, as the entire device has to be inserted into the body. Optical detection with semiconducting SWCNTs is based on the radiative recombination of excitons in the near-infrared (NIR) by prior optical (fluorescence) or electrical excitation (electroluminescence). The emission in the NIR enables detection in the biological transparency window, where optical sensor applications benefit from reduced scattering and autofluorescence of biological samples and consequently a high signal-to-noise ratio. Compared to optical sensors in the UV or visible range, the penetration depth in biological tissue is also increased. In addition to the advantage of a contactless readout SWCNTs have excellent photostability, which enables long-term sensor applications. Furthermore, the nanoscale size of SWCNTs allows dense coating of surfaces which enables chemical imaging, e.g. of cellular release processes with high spatial and temporal resolution.

==== Knight Commander of the Order of St Michael and St George (KCMG) ==== Thomas Drew, , Director General, Defence and Intelligence, Foreign, Commonwealth and Development Office. For services to British Foreign Policy and National Security. Richard Grenville Russell Evans, Chairman, Hemingways Hospitality Ltd. For services to Business, to Sport and to Charity. Crawford Falconer, Chief Trade Negotiation Adviser and Second Permanent Secretary, Department for Business and Trade. For services to International Trade.

== Axial field technology == Axial field technology (AFT) is a patented improvement of DRC made by Perkin-Elmer, which consists in two supplementary rods placed in the DRC cell, smaller than normal quadrupole's rods, with the purpose of "pushing" the ions faster to the exit by generating a supplementary electric potential, minimizing the time needed for the gas to be in the DRC and improving analysis speed. The suplimetary potential of the AFT rods does not contribute significantly to the global energy, but drastically improve ion passage time.

== External links == International Society for Condensed Matter Nuclear Science (iscmns.org), organizes the ICCF conferences and publishes the Journal of Condensed Matter Nuclear Science. See: library.htm of published papers and proceedings. Low Energy Nuclear Reactions (LENR) Phenomena and Potential Applications Archived 7 October 2015 at the Wayback Machine: Naval Surface Warfare Center report NSWCDD-PN-15-0040 by Louis F. DeChiaro, PhD, 23 September 2015

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

Network